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T.E. Starzl 
H UMAN hepatocellular carcinoma (HCC) is a highly 
malignant tumor with a natural history of a few 
months from the time of diagnosis. Curative resection 
offers the best chance of survival. l However, surgical 
resectability rates rarely exceed 30% to 40% because of 
extensiveness of the tumors or because coexisting liver 
disease precludes attempted partial hepatectomy.2 Conse-
quently, total liver removal and replacement have been 
used extensively as a therapeutic option. 3 
Because the rate of recurrence after liver transplantation 
has been high,3-9 it has been speculated that the requisite 
immunosuppressive agents may enhance the recurrence of 
original malignancies by weakening immune surveil-
lance.3- lo In the present study, we have tested this hypoth-
esis by inducing HCC in rats by multiple injections of 
diethylnitrosamine (DEN), followed by isogeneic liver 
transplantation with and without immunosuppression with 
FK 506 and cyclosporine (CyA). The results were incon-
clusive. 
MATERIALS AND METHODS 
Animals and Induction of HCC 
Five- to 6-week-old male Fisher rats (F334) weighing 1 IO to 120 g 
were obtained from Harlan Sprague-Dawley, Inc (Indianapolis, 
IN) and given 75 mg/kg weekly intraperitoneal injections for 3 
weeks of DEN (Sigma Chemical Co, St Louis, MO). followed by 
three further weekly injections of 100 mg/kg. The animals were 
maintained in a special room for carcinogen use with water and 
regular rat chow ad libitum. Isogeneic Fisher rats weighing 200 to 
300 g were kept in a separate room until they were used as liver 
donors. 
Immunologic Testing 
Effector Cells. Mononuclear cells were isolated from the liver 
and spleen of normal Fisher rats and rats with HCC by morcella-
tion of the specimen. and digestion for 15 to 20 minutes in RPMI 
medium (Gibco. Ground Island, NY), which was supplemented 
with 0.05% collagenase (Type 4, Sigma) and 0.002% DNase (Type 
I, Sigma). After passage through nylon mesh, the mononuclear 
cells were separated by Ficoll-Hypaque gradient. In the rats with 
HCC, bits of the liver tumor were processed from which the tumor 
infiltrating lymphocytes (TIL) were purified. 
TarRet Cells. The ability of the purified elfector cells to lyse 
three kinds of cell targets was determined: (I) Y AC-I line for 
natural killer (NK) cell activity, (2) P8151ine for lectin-dependent 
cell cytotoxicity (LDCC) in the presence of 5 J.tg/mL of phytohe-
magglutinin P (Sigma). and (3) HCC cells isolated from a tumor in 
the same rat providing the TIL. The HCC cells were separated 
after enzyme digestion and discontinuous (75/100%) Ficoll-Hy-
paque centrifugation (upper interface). 
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Target cells were placed in 96-well V -bottom plates (Coster. 
Cambridge, MA). and incubated with effector cells at effector/ 
target ratios ranging from 50: I to 6: I. Miniaturized 4-hour 51Cr_ 
release assays in triplicate were performed using I x 103 target 
cells. labeled with 51Cr (5 mCi/mL: New England Nuclear, 
Boston, MAL Maximal and spontaneous release were determined 
by adding 5% Triton X-IOO or medium. respectively. The plates 
were centrifuged at 651{ for 3 minutes and incubated at 37°C in 5% 
CO2 in air for 4 hours. Supernatants were harvested and radioac-
tivity was counted with a beta scintillation counter. The percent 
specific lysis was determined according to the formula: 
% specific lysis = 
experimental release - spontaneous release 
-----------------------------x 100 
maximal release - spontaneous release 
Lytic units of cytotoxicity were calculated according to the 
formula of Pross et al": one lytic unit was defined as the number 
of effector cells needed to lyse 20% of 5 x 10' target cells and 
cytotoxicity was calculated per 1 07 effector cells. 
Immunosuppressive Agents 
Oral FK 506 (Fujisawa Pharmaceutical Co Ltd. Osaka, Japan) 
dispersed with hydroxy propyl methylcellulose (a water-soluble 
polymer), was suspended in water with sonication and used at an 
oral dose of 1.0 mg/kg/d. Oral CyA (Sandoz Ltd. Basel. Switzer-
land) was diluted with olive oil and used at a dose of 10 mg/kg/d. 
Drug administration was started I day after transplantation and 
continued for 150 days by direct instillation with a gastric tube. 
These doses of the two drugs are effective in preventing autoim-
mune diabetes in rats 12.13 and in transplantation. 
OrthotopiC Liver Transplantation 
Orthotopic liver transplantation was performed with a modifica-
tion of the method of Kamada and Calne,14 using the simplified 
cuff technique for the portal vein and infrahepatic vena cava 
anastomosis. Hepatic arterial reconstruction was not performed. 
Recipient animals received lM injection of cefamandole nafate (20 
mg/d) for 3 days po,toperalively. 
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Table 1. Unaltered HCC Development by Histopathology, HCC Size, and Blood Chemistries in 24 Killed Animals 
Blood Chemistries 
Weeks After Mean HCC Total 
Last DEN Histopathologic Lung Size (cm) GOT GPT Bilirubin AKP GGT Albumin 
Injection n Diagnosis Metastasis (Range) (U/L) (U/L) (mg/dL) (U/L) (U/L) (g/dL) 
5-7 9 GST-P positive foci 187 ± 65 96 ± 33 0.05 ± 0.05 176 ± 126 62 ± 40 3.74 ± 0.75 
9-13 7 GST -P positive foci 0.26 122 ± 52 65 ± 35 0.02 ± 0.04 184 ± 26 33 ± 29 3.76 ± 0.42 
and nodule 4 of (0.1-0.5) 
7HCC 
18-25 4 HCC with vascular 1/4 1.7 347 ± 173 335 ± 219 0.08 ± 0.05 231 ± 56 90 ± 48 4.13 ± 0.26 
invasion (0.5-2.0) 
32-40 4 HCC with vascular 2/4 2.15 831 ± 1,122 690 ± 880 0.25 ± 0.13 318 ± 126 291 ± 205 3.73 ± 0.70 
invasion (0.6-5.0) 
Note: Values are mean ± SD 
Abbreviations: GST-P, glutathione S transferase placental form; GOT, glutamie-oxaloacetie transaminase; GPT. glutamic-pyruvic transaminase; AKP, alkaline 
phosphatase; GGT, gamma-glutamyl transpeptitase. 
Experimental Design 
Natural History. A total of 99 rats were entered. of which 6 
were discarded 5 to 22 weeks after completion of the DEN course 
because of their morbid condition. Of the 93 remaining rats. 24 
were followed and killed in cohorts to establish the natural history 
of the induced disease (Table 1). Liver and lung tissues were fixed 
in Stieve solution or Bouin's solution and paraffin embedded. 
Sections were stained for hematoxylin and eosin (H&E) and for 
glutathione S transferase placental form (GST-P), which is a 
marker of preneoplastic and neoplastic lesions of rat liver. 1.' 
Staining was with the avidin-biotin complex (ABC) method using 
antirat GST-P antibody (Bio Prep, Dublin. Ireland). 
Experimental Groups. All the other 69 rats developed HCC and 
were stratified by tumor size into experimental groups. Beginning 
III weeks after completion of DEN. laparotomy was performed. 
Rats with definite HCC nodules < 1.0 cm or with nodules> 1.2 cm 
were submitted immediately to orthotopic liver transplantation or 
consigned to a nontransplant group. The remaining rats with 
undetectable or small tumors were closed and periodically reop-
erated every 3 to 4 weeks until the liver tumors appeared and 
qualified the animal for transplantation by reaching a size > 1.2 
cm. A total of 42 laparotomies and 56 transplantations were 
performed on the 69 animals between 10 and 25 weeks after the 
last injection of DEN. 
Eighteen of 56 transplanted animals died within 7 days after 
surgery, and were excluded from further analysis. Posttransplant 
survival rate (67.9%) was poor when compared with those of other 
studies at our laboratory in which normal healthy rats were 
used. 16 
The rats were placed into the groups summarized in Table 2. 
Except for the animals with small HCC (group 2) that all under-
Table 2. Experimental Groups 
HCC Size 
OLTX at Entry* Immunosuppression 
Group N (Isograft) (em) AfterOLTX 
13 >1.2 
2 10 + <1.0 
3 11 + >1.2 
4 11 + >1.2 FK 506 1.0 mg/kg/d (po) 
5 16 ~ >1.2 CyA 10.0 mg/kg/d (po) 
Abbreviations: OLTX, orthotopic liver transplantation. 
*Entry: See text for time of entry. 
went orthotopic liver transplantation I II weeks after completing 
DEN, the time of orthotopic liver transplantation was evenly 
distributed between 15 and 25 weeks post-DEN. The primary end 
point was duration of survival after transplantation. 
Statistical AnalYSis 
Differences between groups were analyzed by two-tailed Stu-
dent's t test with the level of significance at P < .05. 
RESULTS 
Natural History 
In the animals killed 5 to 13 weeks after completion of 
DEN. 4 of 16 had frank HCC and all of the others had 
hyperplastic nodules or foci with GST-P positive stain that 
identifies premalignant changes (Table 1). Between 18 and 
40 weeks, eight of eight animals had frank HCC and in 
three there were pulmonary metastases. Although only a 
few animals became jaundiced or had hypoalbuminemia. 
the transaminases and alkaline phosphatase were progres-
sively increased (Table I). 
Effector Cell Activity 
The cytotoxicity of N K cells from the liver and spleen of 
HCC bearing rats was significantly reduced from that in 
normal animals (Table 3). The cytotoxicity of NK cells 
from the tumor (TIL) was even more drastically reduced. 
Cytotoxicity against autologous tumor cells was nil. HCC 
status did not affect the cytotoxicity against lectin-depen-
dent target cells (Table 3). 
Effect of Transplantation and Immunosuppression 
The animals not submitted to either isotransplantation or 
immunosuppression lived for a median of 62 days (30 to 
ISO); two had pUlmonary metastases (Table 4). Survival 
was almost doubled by isogeneic transplantation. both in 
animals with small HCCs (group 2) and those with tumors 
> 1.2 cm (group 3). The tumors did not recur in any of the 
transplanted livers in groups 2 and 3, although pulmonary 
metastases were present at the time of death in 3 of the II 
rats of group 3. 
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Table 3. Cytotoxicity of Mononuclear Cells from HCC-Bearing and Normal Rats Against Variable Target Cells 
Target Cells 
Autologous 
YAC·t P815 (-) pa15 (+) HCC Cells 
HCC-bearing rat (n = 3) 
TIL 16 ± 4' 0 0 0 
Liver 55 ± lOt 1 ± 1 26 ± 5 0 
Spleen 196 ± 32t 2 ± 1 26 ± 6 0 
Normal rat (n = 3) 
Liver 246 ± 52 1 ± 1 10 ± 5 ND 
Spleen 337 ± 43 2±2 31 ± 8 ND 
Note: Cytotoxicities are shown in mean ± SO (LU20110' effector cells). Abbreviations: NO, Not determined .• P < .01 vs liver and spleen in HCC-bearing rats. 
t P < .05 vs liver and spleen in normal rats. 
The augmented survival obtained with liver replacement 
alone was reduced to a median of 18 days with FK 506 and 
to 54 days with CyA. Recurrent tumor in the transplanted 
liver of the immunosuppressed rats never was seen. and 
there were no examples of pulmonary metastases in the 15 
experiments of groups 4 and 5. However, two rats devel-
oped squamous cell carcinoma of the lung (in group 4) and 
another (in group 2) had developed a renal cell carcinoma. 
Surgical complications with the liver graft that did not 
have an arterial blood supply were common in all of the 
transplantation groups, and especially in those that in-
cluded immunosuppression. Partial infarction of the livers 
with subsequent abscess formation was better tolerated in 
the nonimmunosuppressed animals than in those given FK 
506 or Cy A. The death of animals with infarcted liver 
usually was due to overwhelming intra-abdominal sepsis 
as well as lung infection. This was particularly evident in 
rats under immunosuppression. 
DISCUSSION 
As expected. these studies showed that isogeneic hepatic 
transplantation could increase survival of rats bearing 
carcinogen-induced HCCs. It has been argued that this 
experimental HCC may not be relevant to human HCC 
because of the large amount of carcinogen administered 
and because the immunogenicity of the resulting tumors is 
high.17 These objections were answered in part by our 
demonstration that the general N K cell activity was de-
pressed in these animals by the presence of HCC. Further-
more. the tumor cells elicited little if any cytotoxic re-
sponse (autologous) from the mononuclear cells of the 
tumor-bearing animals. Similar depressed immunologic 
reactivity is typical in humans with HCC. IS . 19 and has 
prompted a hypothesis that factors produced by human 
HCC cell lines are responsible. 20 
Further exploration of the host-tumor relationships with 
this induced tumor should be fruitful but with the impor-
tant modification that the liver grafts should be arterial-
ized. The liver transplantation technique of Kamada and 
Calne l4 that provides good results in our hands when used 
in healthy animals 16 was not so well tolerated in the rat 
recipients already debilitated by DEN pretreatment. In 
these rats, the portal hemodynamics may have been al-
tered by the DEN-induced liver disease. including a reduc-
tion in portal venous flow and increased dependence on 
the hepatic artery as occurs in humans with cirrhosis. 
There was an extraordinary incidence of regional hepatic 
infarction that caused a high mortality in all animals, but 
Table 4. Animal Survival After Liver Transplantation With/Without Immunosuppression 
HCC (Primary/ 
Reeu rrence) 
Mean Time Complications %of Ani-
Mean From Last DEN % of Animals mals 
HCC Size at Injection to 
Entry' (cm) Entry (d) Median Abscess in 
Group N (Range) (Range) Survival aiter Entry (d) Survival (d) Liver Liver 
13 2.0 148.8 30,37,40,41,44,58,62,75,85,112,123,128,150 62.0 0 100 
(1.2-3.2) (114-173) (13/13) 
2 10 0.8 82.2 8,15,19,33,90,127,157, >196. >196, >205 108.5 40 0 
(0.5-1.0) (66-82) (4/10) 
3 11 1.6 106.3 8,18,17,15,62,101,113,126, >164, >164, >171 101.0 36.4 0 
(1.3-2.0) (103-158) (4/11 ) 
4 11 1.6 125.6 7,8,11,17,18,18,19,70,122,129, >164 18.0 63.6 0 
(1.2-2.0) (107-166) (7/11 ) 
5 6 1.9 144.6 ~ 12, 1~ 94,118, >154 54.0 50 0 
(1.5-3.0) (124-173) (3/6) 
'Entry: See Table 2. Time of entry for group 1, HCC size >1.2 em and no OLTX; group 2, HCC size <1.0 cm and OLTX; groups 3-5, HCC size "1.2 em and OLTX. 
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especially those under immunosuppression whose death 
almost always was due to hepatic or hepatic plus pulmo-
nary sepsis. 
Thus, before it can be determined if hepatic tumor 
recurrence or extrahepatic metastases are accelerated ei-
ther by transplantation itself or by immunosuppression, 
more consistent long-term survival with fully vascularized 
grafts will be a necessary condition. Such a study in rats is 
more apt to resolve these questions than attempts to study 
human cases, which of necessity are uncontrollably heter-
ogeneous.9 With the DEN method of HCC induction, the 
lesion being examined is producible in essentially 100% of 
animals, and its evolution can be determined under a wide 
range of controlled therapeutic variables including trans-
plantation. 
REFERENCES 
1. Nagasue N, Yukaya H, Hamada T, et al: Cancer 54:1461, 
1984 
2. Bismuth H, Houssin D, Omowski J, et al: World J Surg 
10:311, 1986 
3. Starzl TE, Putnam CW: Experience in Hepatic Transplan-
tation. Philadelphia: WB Saunders Company, 1969 
4. Bismuth H, Castaing D, Ericzon BG, et al: Lancet 2:674, 
1987 
751 
5. OttoG, Heuschen UA, Hofmann WJ, etal: Eur J SurgOncol 
16:346, 1990 
6. Ringe B, Wittekind C, Bechstein WO, et al: Ann Surg 
209:88, 1989 
7. O'Grady JG, Polson RJ, Rones K, et al: Ann Surg 207:373, 
1988 
8. Iwatsuki S, Gordon RD, Shaw BW, et al: Ann Surg 202:401, 
1985 
9. Iwatsuki S, Starzl TE, Sheahan DG, et al: Ann Surg (in 
press) 
10. Starzl TE, Penn I, Putnam CW, et al: Transplant Rev 7: 112, 
1971 
11. Pross HF, Baines MT, Rubin P, et al: J Clin Immunol1:51, 
1981 
12. Murase N, Lieberman I, Nalesnik M, et al: Transplant Proc 
23:551, 1991 
13. Laupacis A, Stiller CR, Garden C, et aI: Lancet 1:10, 1983 
14. Kamada N, Caine R: Transplantation 28:47, 1979 
15. Sato K: Adv Cancer Res 52:205, 1989 
16. Murase N, Kim DG, Todo S, et al: Transplantation 50:186, 
1990 
17. Scott OCA: Cancer Res 51:757, 1991 
18. Moy PM, Holmes EC, Golub SH: Cancer Res 45:57, 1985 
19. Miescher S, Whiteside TL, Carrel S, et al: J Immunol 
136:1899,1986 
20. Keong A, Herman J, Rabson AR: Cancer Immunol Immu-
not her 15: 183, 1983 
